Loading, Please Wait...
CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced it will present at each of the following upcoming healthcare conferences:
A live audio webcast of each presentation will be available under the “Events and Presentations” section of LogicBio’s website. A replay of each presentation will become available approximately one hour after the event and will be archived for 30 days.
About LogicBio Therapeutics
LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using, GeneRide™, its proprietary technology platform. GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive lifelong expression. Headquartered in Cambridge, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.
For more information, please visit www.logicbio.com.
Stern Investor Relations
Stephanie Simon, Ten Bridge Communications